consider ahead result
provid busi updat highlight strong year execut
encourag outlook review key consider result
includ long-term revenu growth strategi base increas volum
geograph expans recent launch product pipelin advanc
focus oncolog cv inflamm asset sever data readout
biosimilar becom increasingli import sourc revenu financi
flexibl continu follow invest bd opportun
continu capit return sharehold expect manag remain financi
disciplin forecast steadi cash flow oper margin expans
updat model script rais pt
forecast revenu adj ep line consensu
estim long-term revenu outlook gener line consensu
increas steadili oper margin
expand expect remain financi disciplin
focus capit alloc cost manag exhibit
highlight strateg focu volume-driven revenu growth
geograph expans recent launch product repatha even
blincyto bgne collabor open larg potenti oncolog asset china
second-largest oncolog market astella jv revert wholly-
own subsidiari japan anticip sale growth
specif asia-pacif region within ten year exhibit
pipelin catalyst unlock signific valu kras-
inhibitor trial nsclc complet enrol initi data expect
also await combin data anti-bcma bite mm
initi clinic data expect read-out addit readout
includ tezepelumab severe/uncontrolled-asthma omecamtiv mercarbil
cv-outcom data otezla mild/moderate-psoriasi data
biosimilar increasingli becom growth driver annual
note strong us sale kanjinti mvasi receiv
us approv biosimilar remicad submit bla biosimilar rituxan
current domin market share ex-u market
comment biosimilar could becom multi-billion dollar opportun
updat model reflect script continu track recent us
launch repatha aimovig re-affirmed commit prudent
capit alloc return valu dividend share buyback
note sinc invest return cash
sharehold remain bullish ahead updat exhibit
year price histori
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel stabl
next year margin continu expand
manag track record financi disciplin
top line believ posit maintain long-term
revenu stabil matur product declin new product
continu grow pipelin deliv steadi flow new
product addit offer dividend yield
believ provid valuat support
updat data kra inhibitor major
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top line essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
exhibit oppenheim vs consensu estim
exhibit revenu forecast increas steadili
incom estimate oppenheim vs consensu actual oppenheim estimate vs consensu updat midpoint total non-gaap cog margin rate incom ep estimate oppenheim vs consensu actual oppenheim estimate vs consensu revenu estim pipelinehpt secondari ckdprimari caredenosumaboncologyauto-immunegrowth factorsoth inc
exhibit highlight strateg focu drive intern growth
exhibit invest busi return cash sharehold sinc
exhibit dcf valuat support pt includ bgne incom equiti account
amgndiscount analysi except per-shar data revenu incom chang work work capit valu growth valu oppenheim estim compani reportsequ valu per sharetermin valu growth rate inc
bgne net incom
